Garfield, Joshua B. B. http://orcid.org/0000-0002-5076-6499
Piercy, Hugh
Arunogiri, Shalini
Lubman, Dan I.
Campbell, Samuel C.
Sanfilippo, Paul G.
Gavin, Jeff
Hopwood, Malcolm
Kotler, Eli
George, Suzanne
Okedara, Goke
Piccoli, Lara R.
Manning, Victoria
Funding for this research was provided by:
National Centre for Clinical Research on Emerging Drugs (NCR2SF10)
Article History
Received: 26 March 2020
Accepted: 21 November 2020
First Online: 6 January 2021
Ethics approval and consent to participate
: This study has been reviewed and approved by the Eastern Health Human Research Ethics Committee (project number: E19/022/58264) and the Monash University Human Research Ethics Committee (project number: 23080). All participants provide written consent to participate after receiving a full written and verbal explanation of the study’s aims, procedures, and risks.
: Not applicable.
: DIL has provided consultancy advice to Lundbeck and Indivior and has received travel support and speaker honoraria from Astra Zeneca, Janssen, Lundbeck, Shire, and Servier, though none of these organisations stand to benefit from the current project. DIL has been an investigator on an untied education grant from Sequirus, unrelated to the current work. MH has provided consultancy advice to Lundbeck, Servier, and Janssen-Cilag and has received travel support, speaker honoraria, or research funding from Lundbeck, Servier, Janssen-Cilag, Praxis, Lyndra, and Boehringer-Ingelheim, though none of these organisations stand to benefit from the current project. The authors have no other competing interests to declare.